DPP4 and Parkinson disease: Another preclinical study of DPP4 inhibitors, also known as gliptins (sitagliptin and PF-00734,200), that used the 6-OHDA rat model of PD revealed several beneficial findings, such as dopaminergic cell preservation and DA level protection [106].